AbbVie EBITDA 2010-2024 | ABBV
AbbVie annual and quarterly EBITDA history from 2010 to 2024. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- AbbVie EBITDA for the quarter ending September 30, 2024 was $5.910B, a 30.87% increase year-over-year.
- AbbVie EBITDA for the twelve months ending September 30, 2024 was $22.182B, a 6.97% decline year-over-year.
- AbbVie 2023 annual EBITDA was $21.455B, a 19.29% decline from 2022.
- AbbVie 2022 annual EBITDA was $26.584B, a 0.53% increase from 2021.
- AbbVie 2021 annual EBITDA was $26.445B, a 48.28% increase from 2020.
AbbVie Annual EBITDA
(Millions of US $) |
| 2023 |
$21,455 |
| 2022 |
$26,584 |
| 2021 |
$26,445 |
| 2020 |
$17,834 |
| 2019 |
$15,000 |
| 2018 |
$8,148 |
| 2017 |
$11,046 |
| 2016 |
$10,529 |
| 2015 |
$8,373 |
| 2014 |
$4,197 |
| 2013 |
$6,561 |
| 2012 |
$6,967 |
| 2011 |
$4,892 |
| 2010 |
$5,901 |
| 2009 |
$5,629 |
AbbVie Quarterly EBITDA
(Millions of US $) |
| 2024-09-30 |
$5,910 |
| 2024-06-30 |
$6,129 |
| 2024-03-31 |
$4,872 |
| 2023-12-31 |
$5,271 |
| 2023-09-30 |
$4,516 |
| 2023-06-30 |
$6,773 |
| 2023-03-31 |
$4,895 |
| 2022-12-31 |
$7,659 |
| 2022-09-30 |
$6,808 |
| 2022-06-30 |
$5,347 |
| 2022-03-31 |
$6,770 |
| 2021-12-31 |
$7,053 |
| 2021-09-30 |
$6,433 |
| 2021-06-30 |
$6,641 |
| 2021-03-31 |
$6,318 |
| 2020-12-31 |
$5,818 |
| 2020-09-30 |
$5,547 |
| 2020-06-30 |
$2,307 |
| 2020-03-31 |
$4,162 |
| 2019-12-31 |
$4,465 |
| 2019-09-30 |
$3,120 |
| 2019-06-30 |
$3,902 |
| 2019-03-31 |
$3,513 |
| 2018-12-31 |
$-1,999 |
| 2018-09-30 |
$3,594 |
| 2018-06-30 |
$3,205 |
| 2018-03-31 |
$3,348 |
| 2017-12-31 |
$2,151 |
| 2017-09-30 |
$3,073 |
| 2017-06-30 |
$3,041 |
| 2017-03-31 |
$2,781 |
| 2016-12-31 |
$2,642 |
| 2016-09-30 |
$2,665 |
| 2016-06-30 |
$2,676 |
| 2016-03-31 |
$2,546 |
| 2015-12-31 |
$2,374 |
| 2015-09-30 |
$2,112 |
| 2015-06-30 |
$2,042 |
| 2015-03-31 |
$1,845 |
| 2014-12-31 |
$-222 |
| 2014-09-30 |
$1,152 |
| 2014-06-30 |
$1,717 |
| 2014-03-31 |
$1,550 |
| 2013-12-31 |
$1,735 |
| 2013-09-30 |
$1,605 |
| 2013-06-30 |
$1,689 |
| 2013-03-31 |
$1,532 |
| 2012-12-31 |
$2,130 |
| 2012-09-30 |
$1,823 |
| 2012-06-30 |
$1,717 |
| 2012-03-31 |
$1,297 |
| 2011-12-31 |
$-5,562 |
| 2011-09-30 |
$4,724 |
| 2011-06-30 |
$4,592 |
| 2011-03-31 |
$1,139 |
| 2010-12-31 |
|
| 2009-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$294.353B |
$54.318B |
|
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
|
